Myocardial imaging: IV: Dosage range: 10 to 20 mCi (0.368 to 0.736 GBq)
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, for injection: 3.75-37.5 mCi/mL (20 mL)
Yes
IV: For IV administration. Administer as a bolus through a catheter inserted into a large peripheral vein. Radiopharmaceutical; use appropriate precautions for handling and disposal. Ensure adequate hydration before and after administration. To minimize bladder exposure, patients should void frequently.
Rest imaging: Administer as a single dose; start imaging 3 minutes after administration and acquire images for a total of 10 to 20 minutes.
Stress imaging: Begin study at least 40 minutes after completion of rest imaging dose. Administer pharmacologic stress agent; after 8 minutes, administer single dose of nitrogen 13 ammonia; start imaging 3 minutes after administration and acquire images for a total of 10 to 20 minutes.
Myocardial imaging: Radiopharmaceutical imaging agent used in conjunction with positron emission tomography (PET) to detect pericardial perfusion of the myocardium in patients with suspected or existing coronary artery disease.
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
There are no contraindications listed within the manufacturer’s labeling.
Concerns related to adverse effects:
• Malignancy: Radiation-emitting products may increase the risk for cancer; use the smallest dose necessary and ensure safe handling to protect patients and health care workers.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Appropriate use: Test may be done while patients are at rest or under pharmacologic stress conditions. Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for at least 1 hour following administration to decrease radiation exposure to the bladder.
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted.
It is not known whether this drug is excreted in human milk. The manufacturer recommends that stored breast milk or formula feedings be substituted until at least 2 hours after administration.
Radioactive diagnostic agent which decays by emitting positron to carbon C-13 a photon that can be detected by imaging.
Metabolism: Hepatic; undergoes five-enzyme step to form urea N-13. Also under goes glutamine synthesis forming glutamine N-13.
Half-life elimination: Biological half-life: 2.84 minutes (blood) and <2 minutes (myocardium); Physical half-life: ~10 minutes
Time to peak: Myocardium uptake: 10 to 20 minutes
Excretion: Urine (mainly as urea N-13)